Alnylam pharmaceuticals joins alliance for genomic discovery, expanding diverse clinical genomic dataset to drive precision medicine

Alnylam, a leader in rna interference (rnai) therapeutics, will utilize the agd dataset to inform development of 'gene silencing' medicines members leverage ai-powered dataset to accelerate pharma r&d, and ensure that disease-impacting discoveries benefit all people san diego , sept. 18, 2025 /prnewswire/ -- illumina, inc. (nasdaq: ilmn), and nashville biosciences, llc (nashbio), today announced alnylam pharmaceuticals, inc. (nasdaq: alny) (alnylam) as a member of the alliance for genomic discovery (agd).
ALNY Ratings Summary
ALNY Quant Ranking